Pink1 Parkin Pathway In Parkinson'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The PINK1 (PTEN-induced kinase 1) and Parkin (PARK2) genes encode proteins that work together in the mitochondrial quality control pathway known as mitophagy. Biallelic loss-of-function mutations in either gene cause autosomal recessive juvenile-onset Parkinson's disease (PD), making this pathway critically important for understanding PD pathogenesis[1].
PINK1 is a serine/threonine-protein kinase that acts as a mitochondrial damage sensor, while Parkin is an E3 ubiquitin ligase that executes the removal of damaged mitochondria. Together, they form the core of the mitochondrial quality control system[2].
PINK1 (encoded by the PINK1 gene on chromosome 1p36) is a 581-amino acid protein with:
Under normal conditions:
Upon mitochondrial damage:
Parkin (encoded by the PARK2 gene on chromosome 6q26) is a 465-amino acid E3 ubiquitin ligase with:
Under normal conditions:
Upon activation:
Parkin ubiquitinates numerous OMM proteins:
| Feature | PINK1-PD | Parkin-PD |
|---|---|---|
| Age of onset | 30-50 years | <20-40 years |
| Disease progression | Slow | Variable |
| Levodopa response | Good | Excellent |
| Cognitive decline | Rare | Rare |
| Dystonia | Uncommon | Common |
The study of Pink1 Parkin Pathway In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
Recent advances in PINK1/Parkin-mediated mitophagy have revealed new insights:
PINK1-Parkin Pathway can be explored through the following Allen Brain Atlas resources:
Kane LA et al. PINK1 phosphorylates ubiquitin to activate parkin E3 ubiquitin ligase activity. J Cell Biol. 2014. ↩︎ ↩︎ ↩︎
Lazarou M et al. PINK1-Parkin mitochondrial ubiquitylation pathway controls a broader mitochondrial quality control system. Mol Cell. 2015. ↩︎ ↩︎
Narendra D et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010. ↩︎ ↩︎ ↩︎
Gegg ME et al. Mitofusin 1 and mitofusin 2 are ubiquitinated by parkin and mediate mitochondrial fusion. Cell Cycle. 2010. ↩︎
Geisler S et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010. ↩︎
Valente EM et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004. ↩︎
Kitada T et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998. ↩︎
Corti O et al. Molecular and cellular biology of the neuronal PINK1/parkin pathway in health and disease. Brain Res. 2005. ↩︎
McGeer PL et al. Parkinson disease: update on neurodegenerative processes. Ann Neurol. 2003. ↩︎